Oral β-glucan and vaccine response in individuals with metastatic neuroblastoma

Individuals with high-risk relapsed metastatic neuroblastoma set to receive the GD2/3 vaccine were split into two groups to assess the effect of oral β-glucan during vaccine priming.
The addition of oral β-glucan during vaccine priming resulted in a higher stimulated IgG antibody response (P=0.08) with no toxic adverse effects, however; there were no differences in seroconversion rates between groups
The authors concluded that while IgG antibody response is increased, this does not directly lead to increased seroconversion so further research is required for oral β-glucan to have direct clinical implications.